Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan

Reuters11-11
Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan

Crinetics Pharmaceuticals Inc. has granted non-qualified stock options to purchase a total of 37,675 shares and 25,300 restricted stock units (RSUs) to 11 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The stock options carry an exercise price of $41.45 per share, equal to the company's closing stock price on November 10, 2025. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following three years. The RSUs will vest in equal annual installments over four years, beginning on the first anniversary of the grant date. Both awards are subject to the employees' continued employment with Crinetics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572857-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment